A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance

Lei Sun,Arabella H. Wan,Shijia Yan,Ruonian Liu,Jiarui Li,Zhuolong Zhou,Ruirui Wu,Dongshi Chen,Xianzhang Bu,Jingxing Ou,Kai Li,Xiongbin Lu,Guohui Wan,Zunfu Ke

DOI: https://doi.org/10.1016/j.apsb.2023.09.015

IF: 14.903

2023-09-27

Acta Pharmaceutica Sinica B

Abstract:Lenvatinib, a second-generation multi-receptor tyrosine kinase inhibitor approved by the FDA for first-line treatment of advanced liver cancer, facing limitations due to drug resistance. Here, we applied a multidimensional, high-throughput screening platform comprising patient-derived resistant liver tumor cells (PDCs), organoids (PDOs), and xenografts (PDXs) to identify drug susceptibilities for conquering lenvatinib resistance in clinically relevant settings. Expansion and passaging of PDCs and PDOs from resistant patient liver tumors retained functional fidelity to lenvatinib treatment, expediting drug repurposing screens. Pharmacological screening identified romidepsin, YM155, apitolisib, NVP-TAE684 and dasatinib as potential antitumor agents in lenvatinib-resistant PDC and PDO models. Notably, romidepsin treatment enhanced antitumor response in syngeneic mouse models by triggering immunogenic tumor cell death and blocking the EGFR signaling pathway. A combination of romidepsin and immunotherapy achieved robust and synergistic antitumor effects against lenvatinib resistance in humanized immunocompetent PDX models. Collectively, our findings suggest that patient-derived liver cancer models effectively recapitulate lenvatinib resistance observed in clinical settings and expedite drug discovery for advanced liver cancer, providing a feasible multidimensional platform for personalized medicine.

pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to overcome the resistance of Lenvatinib to liver cancer treatment in the clinical setting. Lenvatinib is a multi - receptor tyrosine kinase inhibitor and has been approved by the FDA for the first - line treatment of advanced liver cancer. However, patients usually develop resistance within 1 - 2 years after treatment with Lenvatinib, which limits its long - term efficacy. In order to find effective alternative or combined treatment methods, researchers have developed a multi - dimensional high - throughput screening platform, using patient - derived tumor cells (PDCs), organoids (PDOs) and xenograft models (PDXs) to identify drugs that can overcome Lenvatinib resistance.

Through this platform, researchers have discovered some potential anti - tumor drugs, such as Romidepsin, YM155, Apitolisib, NVP - TAE684 and Dasatinib. In particular, Romidepsin not only enhances the anti - tumor response, but also plays a role by triggering immunogenic tumor cell death and blocking the EGFR signaling pathway. In addition, the combined use of Romidepsin and immunotherapy has shown a strong synergistic anti - tumor effect in humanized immune - competent PDX models.

In conclusion, this study provides an effective method to identify and validate treatment strategies for liver cancer with Lenvatinib resistance, providing new tools and ideas for personalized medicine.